Diagnostic utility of the insulin-to-C-peptide molar ratio in differentiating insulin autoimmune syndrome and exogenous insulin antibody syndrome from insulinoma - Scorecard - MDSpire
Advertisement
Diagnostic utility of the insulin-to-C-peptide molar ratio in differentiating insulin autoimmune syndrome and exogenous insulin antibody syndrome from insulinoma
Clinical Scorecard: Evaluating the Insulin-to-C-Peptide Molar Ratio for Differentiating Insulin Autoimmune Syndrome and Exogenous Insulin Antibody Syndrome from Insulinoma
At a Glance
Category
Detail
Condition
Insulin Autoimmune Syndrome and Exogenous Insulin Antibody Syndrome
Key Mechanisms
Dissociation between insulin and C-peptide levels due to insulin autoantibodies.
Target Population
Patients with suspected insulin autoimmune syndrome or exogenous insulin antibody syndrome.
Care Setting
Clinical biochemical assessment in a hospital setting.
Key Highlights
Insulin-to-C-peptide molar ratio > 1 is traditionally suggestive of IAS but may not be optimal.
Optimal cutoffs for IAS and EIAS were identified as 0.382 and 0.552 during hypoglycemia, respectively.
Insulin concentration alone also showed good diagnostic performance for IAS with AUCs of 0.985 during hypoglycemia.
Guideline-Based Recommendations
Diagnosis
Use insulin-to-C-peptide molar ratio for distinguishing IAS and EIAS from insulinoma.
Management
Consider lower cutoffs for insulin-to-C-peptide molar ratio to improve sensitivity.
Monitoring & Follow-up
Monitor insulin and C-peptide levels during hypoglycemic episodes.
Risks
Failure to recognize IAS and EIAS may lead to severe hypoglycemia and unnecessary investigations.
Patient & Prescribing Data
Patients with IAS and EIAS.
Insulin concentration and insulin-to-C-peptide molar ratio are key diagnostic tools.
Clinical Best Practices
Integrate clinical and laboratory findings for diagnosis.
